Jefferies lowered Kenvue Inc.’s price target to $23 from $25, citing macroeconomic challenges impacting consumer health stocks. Deutsche Bank also reduced the price target to $18 from $20. Meanwhile, Starboard Value CEO Jeff Smith mentioned the company is exploring options to maximize shareholder value through collaboration between management and the board.

Kenvue Inc. (NYSE: KVUE) operates in the US, Europe, Middle East, Africa, Asia-Pacific, and Latin America across three segments: Self Care, Skin Health and Beauty, Essential Health. While KVUE shows investment potential, some believe other AI stocks offer greater upside and less downside risk. For more on undervalued AI stocks, check out the report on the best short-term AI stock.

For more insights on potential stocks and investments, visit Insider Monkey’s articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This information was originally published on Insider Monkey’s website.

Read more at Yahoo Finance: Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health